The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Season’s Greetings

by

As the end of the year draws nears, we would like to thank our members, sponsors, partners, and many volunteers for their participation and contributions. With this help, we had a very productive year. In particular, we co-organized two Symposia in 2021, and launched our Career Shorts interviews and webinar series on Antibody Discovery & Development, Commercializing Antibody Therapeutics, and Adaptive Immune Receptor Repertoires.

In case you missed either Symposia, recordings from our Emerging Immunotherapeutics for Ovarian Cancer Symposium (co-organized with the Ovarian Cancer Research Alliance) and Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium (co-organized with LAVA Therapeutics) are available On Demand on our YouTube channel.

The Career Shorts interviews are also available on our YouTube channel. In this series, scientists and individuals working within the world of antibodies discuss the experiences that have shaped their careers. In sharing their experiences and advice, we aim to empower the next generation of scientists and leaders working in this field to make confident and informed decisions. Career Shorts is the creation of an exceptionally talented volunteer, Raquel Barroso Ferro.

We hope you will join us in our activities in 2022. In particular, The Adaptive Immune Receptor Repertoire (AIRR) Community of The Antibody Society will hold their 6th meeting during May 16-19, 2022. The “Exploring New Frontiers” meeting will be held in person in La Jolla, CA. The AIRR Community is a research-driven group that is organizing and coordinating stakeholders in the use of next-generation sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Our volunteer experts in antibody engineering, Drs. Alicia Chenoweth and Silvia Crescioli, will apply their formidable knowledge of this area to create a searchable table of antibody therapeutics in late-stage clinical studies that will appear online in Q1 2022. Their very useful searchable table of antibody therapeutics that are approved or in review in the European Union or United States is already online.

In addition, we are planning a Symposium on Biopharmaceutical Informatics, tentatively scheduled for September 2022, and we will start a new Graduate Student/Post-doc Research Competition. When available, details for these new programs will be posted on our website and sent via email to members.

Our best wishes to you and yours for a wonderful holiday and a happy new year in 2022!

Xevudy (sotrovimab) approved in the EU for COVID-19

by

On December 17, 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Commission has granted a marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. Sotrovimab is now approved in the European Union for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Sotrovimab, a human anti-SARS-CoV-2 IgG1 antibody derived from the B cell of a COVID-19 survivor, was engineered to achieve high concentration in the lungs and to have an extended half-life.

The marketing application included data from the randomized, double-blind, placebo-controlled Phase 1/2/3 COMET-ICE trial (NCT04545060), which evaluated the effects of sotrovimab in non-hospitalized adults with mild-to-moderate COVID-19 symptoms and a positive SARS-CoV-2 test result. Patients received a single intravenous dose of 500 mg sotrovimab or placebo. Study results showed that treatment with sotrovimab resulted in a 79% reduction in all-cause hospitalizations for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. In total, 30 (6%) of the 529 patients in the placebo arm progressed, compared to six (1%) of the 528 patients receiving sotrovimab.

Sotrovimab is authorized for emergency use in the US, conditional or provisional marketing authorizations in Great Britain, Australia, and Saudi Arabia, as well as temporary authorizations in other countries. Sotrovimab is administered as a 500-milligram single IV dose given over 30 minutes by health care providers. The product has, however, also been formulated for IM administration. In the randomized, open-label COMET-TAIL Phase 3 trial, which achieved its primary endpoint, IM administration of sotrovimab was non-inferior to IV administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalized adults and adolescents (12 years of age and older).

FDA approves Tezspire™ (tezepelumab-ekko) for severe asthma

by

On December 17, 2021, Amgen announced that the U.S. Food and Drug Administration approved Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezepelumab (AMG157, MEDI-9929) is a human IgG2 antibody that targets a cytokine, thymic stromal lymphopoietin, that plays a key role in asthma inflammation. The drug was developed by Amgen in collaboration with AstraZeneca.

The approval was based in part on data from the randomized, placebo-controlled Phase 3 NAVIGATOR study (NCT03347279), which evaluated the effects of tezepelumab in adults and adolescents with severe uncontrolled asthma. In this study, patients received tezepelumab (210 mg; n=529) or placebo (n=532) SC every 4 weeks for 52 weeks. The primary outcome measure of the study, the annualized asthma exacerbation rate from baseline to Week 52, was met. For the tezepelumab group, the annualized rate of asthma exacerbations was 0.93 (95% CI, 0.80 to 1.07), while the rate was 2.10 (95% CI, 1.84 to 2.39) with placebo (rate ratio, 0.44; 95% CI, 0.37 to 0.53; P<0.001). Overall, data from the study indicated that, compared to those administered placebo, patients who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life.104 A pre-specified exploratory analysis showed that tezepelumab reduced the annualized asthma exacerbation rate in patients with nasal polyps by 86% (95% CI: 70, 93) and 52% (95% CI: 42, 61) in those without nasal polyps over 52 weeks compared to placebo given with standard of care.

Marketing applications for Tezspire are under regulatory review in the EU, Japan and several other countries around the world.

FDA approves VYVGARTô (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis

by

On December 17, 2021, argenx SE announced that the US Food and Drug Administration approved VYVGARTô (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Efgartigimod is an IgG1 Fc fragment designed for increased affinity for the neonatal Fc receptor (FcRn). It competes with IgG to occupy FcRn and reduce overall IgG recycling. Efgartigimod was derived from the ABDEG (antibodies that enhance IgG degradation) technology developed by Prof. Sally Ward and colleagues.

FDA’s approval of VYVGART is based on results from the global Phase 3 ADAPT trial, which met its primary endpoint. Trial results demonstrated that significantly more anti-AChR antibody positive gMG patients were responders on the MG-ADL scale following treatment with VYVGART compared with placebo (68% vs. 30%; p<0.0001). There were also significantly more responders on the Quantitative Myasthenia Gravis (QMG) scale following treatment with VYVGART compared with placebo (63% vs. 14%; p<0.0001).

Marketing authorization applications for efgartigimod for the treatment of gMG are currently under review in Japan and the European Union, with anticipated decisions in the first quarter and second half of 2022, respectively.

The Antibody Society announces the election of key Officers and Board of Directors Chair

by

The Antibody Society, Inc., an international non-profit trade association focused on the advancement of antibody research and development, is pleased to announce the election of Prof. E. Sally Ward as President, Dr. Janine Schuurman as Vice President, and Prof. Paul Parren as Chair of the Board of Directors. They will assume these roles on January 1, 2022.

Prof. Ward, Dr. Schuurman and Prof. Parren bring substantial experience and expertise to their new roles. They each have made seminal contributions to the field of antibody discovery and development, and have critical experience with building successful external collaborations, partnerships, and alliances, which are essential to the Society’s future growth. Prof. Parren is succeeding Dr. James S. Huston who founded the Society in 2007 and served as Chair of the Board until his passing in 2020.

Prof. Ward served as the Society’s Vice President during 2020-2021. On her election as President, she said, “I am delighted to be given the opportunity to serve as President for The Antibody Society. It is a particular pleasure to be following in the footsteps of my friend and colleague, Dr. Paul Carter, who has made enormous contributions to the Society during his term. I am very enthusiastic about working with our newly elected Vice President, Dr. Janine Schuurman, on the Executive Committee. The antibody field continues to deliver an ever-expanding repertoire of novel classes of therapeutics to treat human disease, and it is great to be involved in this exciting area!”

Dr. Schuurman stated, “The Antibody Society plays a key role in representing individuals and organizations involved in the antibody research and development and it is a great pleasure to be elected as Vice President of this important association. I’m looking forward to elevating the awareness of antibody science and therapeutics, our beloved field of research, which is getting more and more interdisciplinary and interconnected. I’m also excited about this opportunity to work with Prof. Sally Ward and Dr. Janice Reichert as part of the Society’s Executive Committee.”

Prof. Parren remarked, “I am honored to be elected as the Chair of the Board of The Antibody Society and serve to support the business of antibody therapeutic development by stimulating the interchange of ideas and education as well as by working with opinion leaders and policy makers to forward this exciting field.”

Sally Ward, Ph.D., Professor in Molecular Immunology and Director of Translational Immunology in the Centre for Cancer Immunology at the University of Southampton.

Prof. Ward’s research takes an interdisciplinary approach involving a combination of antibody/protein engineering, fluorescence imaging and in vivo studies to inform the design of antibody-based therapies for autoimmunity and cancer. In 1996, her laboratory identified the Fc receptor, FcRn, as a global regulator of IgG levels, leading to half-life extension and FcRn antagonist (Abdeg) technologies. These technologies have been licensed to biopharma, resulting in engineered, antibody-based therapeutics that are approved or are pending approval. Recent work in her laboratory has also described the generation of antibody-drug conjugates with engineered variable domains that have improved lysosomal delivery behavior.

Janine Schuurman, Ph.D., Senior Vice President, Head Antibody Research & Technology, Genmab

Dr. Schuurman is an expert in antibody biology and translational research. Following her passion to develop innovative antibody therapeutics, Dr. Schuurman joined Genmab in 2000. She currently heads the Research & Technology division, focusing on antibody biology research, the creation of novel antibody formats and their translation to antibody therapeutics. She is a co-inventor multiple antibody technology platforms including DuoBody®, HexaBody® and HexElect® technologies that enable the generation of bispecific and effector-function enhanced antibodies. These technologies are being applied to antibody therapeutics discovery programs at Genmab, as well as many leading pharmaceutical and biotechnology companies located worldwide. In addition, she is a co-inventor of several antibody therapeutic products in various stages of development and approved treatment options for patients.

Paul Parren, Ph.D., Executive Vice President and Head of R&D, Lava Therapeutics; Professor of Molecular Immunology at the Leiden University Medical Center

Prof. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He has a passion for investigating and understanding structure-function relationships and their application in antibody drug discovery and development. He was a postdoc and faculty member at The Scripps Research Institute in La Jolla, CA. From 2002-2017, he served in the position Scientific Director heading Genmab’s preclinical R&D, where he developed the scientific concepts and translation of the DuoBody® and HexaBody® technologies. He is an inventor of five marketed therapeutic antibodies, including canonical human antibodies, an antibody-drug conjugate and a bispecific antibody, approved for the treatment of various cancers and autoimmune inflammatory diseases. He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden, the Netherlands. He heads R&D at LAVA Therapeutics since 2018. Under his leadership, LAVA grew to a clinical stage biotechnology company with a successful initial public offering and Nasdaq listing in the US in March of 2021. He also provides drug development, patent, and investment advice as an independent consultant to (start-up) biotech and pharma and contributes to the program of leading scientific conferences in the antibody field.

About The Antibody Society

The Antibody Society, Inc. is an international non-profit trade association representing individuals and organizations involved in antibody research and development. The Society is an authoritative source of information about antibody therapeutics development, which is disseminated via our website, presentations, and publications. In addition, the Society organizes conferences and webinars on antibody research and development and related topics. The Society also serves as the home for the Adaptive Immune Receptor Repertoire Community, which focuses on developing standards and protocols for curating, analyzing and sharing antibody B and T cell receptors. As a business association, the Society can engage with government and international agencies such as the World Health Organization to discuss topics that are important to the antibody community, such as international naming conventions.